Coronavirus (COVID-19) News
Filter News
Found 2,648 articles
-
Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents
1/3/2024
Invivyd, Inc. announced that it has requested Emergency Use Authorization from the U.S. Food and Drug Administration for VYD222, a broadly neutralizing, half-life extended monoclonal antibody candidate, for the pre-exposure prevention of COVID-19 in immunocompromised adults and adolescents.
-
Enable Biosciences Inc. Reveals Key Findings on COVID-19 Transmission from Mothers to Newborns
1/3/2024
Enable Biosciences Inc. has achieved a breakthrough in understanding maternal SARS-CoV-2 infection and its impact on newborns.
-
A court in Germany on Tuesday nullified one of CureVac’s intellectual property rights in a patent case against BioNTech. However, court proceedings involving seven other patent rights will continue.
-
Novavax's Updated COVID-19 Vaccine Receives Emergency Use Authorization in Taiwan
12/18/2023
Novavax, Inc. announced that the Taiwan Food and Drug Administration has granted emergency use authorization for Nuvaxovid™ XBB.1.5 dispersion for injection COVID-19 Vaccine for active immunization to prevent COVID-19 in individuals aged 12 and older.
-
Another Flagship-founded company is shutting down its operations, according to an SEC filing. Axcella Health, which was focused on the development of a long COVID therapeutic, is no more.
-
BioSpace spoke to analysts and players in the contract manufacturing and development organizations space to assess the challenges this year and what lies ahead in 2024.
-
Novavax's Updated Protein-based COVID-19 Vaccine Now an Option for All 194 Member States of the World Health Organization
11/28/2023
Novavax, Inc. announced that Nuvaxovid™ XBB.1.5 COVID-19 Vaccine has been granted Emergency Use Listing by the World Health Organization for active immunization to prevent COVID-19 in individuals aged 12 and older.
-
Junshi Biosciences Announces Lancet Infectious Diseases Publication of Results from the 2nd Phase 3 Study of VV116 for Treating COVID-19
11/23/2023
Shanghai Junshi Biosciences Co., Ltd announced a new publication in the Lancet Infectious Diseases.
-
Novel MRI Reveals Brain Changes in Long-COVID Patients
11/22/2023
People with long COVID exhibit patterns of changes in the brain that are different from fully recovered COVID-19 patients, according to research being presented next week at the annual meeting of the Radiological Society of North America.
-
Inhalon Biopharma Secures U.S. Army Medical Research and Development Command Award to Support Development of Inhaled Therapeutics for Treatment of COVID-19
11/15/2023
Inhalon Biopharma announced that it has been awarded a $5.7 million contract by the U.S Army Medical Research and Development Command to support a U.S. Army Military Performance Advancement Initiative project to develop new treatments for COVID-19 and other SARS infections.
-
The vaccine maker is prepared to cut another $300 million in operating expenses in 2024 to keep the company afloat as it works to get its combination COVID-19/flu vaccine into Phase III.
-
Senhwa Biosciences Announces First Patient Successfully Dosed in Taiwan Phase II Study of Silmitasertib in Hospitalized Adults with COVID-19
11/9/2023
Senhwa Biosciences, Inc. announced that their first patient has been successfully dosed in Taiwan Phase II Study of Silmitasertib in Hospitalized Adults with COVID-19.
-
A Comparative Analysis of Two SARS-CoV-2 Vaccines: Insights from Korea University College of Medicine
11/9/2023
GBP510, a recombinant vaccine against COVID-19, adjuvanted with AS03, has shown to be highly immunogenic and well tolerated in healthy adults.
-
FDA Clears First COVID-19 Home Antigen Test
11/9/2023
The U.S. Food and Drug Administration cleared for marketing the first over-the-counter antigen test for COVID-19. ACON Laboratories' Flowflex COVID-19 Antigen Home Test, originally authorized for emergency use in 2021, is now the second home COVID-19 test to successfully complete a traditional FDA premarket review pathway, and the first indicated for use in children under 18.
-
Battelle Part of Team Selected to Support New Technologies to Prepare for Future COVID-19 Outbreaks
11/8/2023
As part of the federal $5 billion Project NextGen program, Battelle was awarded $6.1 million from the BARDA to advance human lung and airway tissue chip platform technology, also known as “organ on a chip.” The award is part of BARDA’s indefinite delivery/indefinite quantity contract with Battelle.
-
Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
11/8/2023
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, reported financial results for the third quarter ended September 30, 2023 and provided a business update.
-
African Ginger Patented for Influenza and SARS-CoV-2 Treatment: Insights from M2Bio Sciences Research Chair
11/3/2023
Institute of Biomedical Research Corp. is pleased to provide the following update.
-
While Moderna’s total revenue for the third quarter beat analyst expectations, the company Thursday reported a loss as demand for its COVID vaccines declined.
-
Longhorn Vaccines and Diagnostics to Present Data on Mycobacterium Tuberculosis Vaccine Candidate, LHNVD-301, at The Union World Conference on Lung Health 2023
11/2/2023
Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, will present new data from an animal study of LHNVD-301, the company’s tuberculosis vaccine candidate, at The Union World Conference on Lung Health 2023.
-
Pfizer, Moderna, Novavax and more are working to combine preventative shots for COVID-19, flu, RSV and other illnesses. Will convenience be enough to overcome vaccine fatigue?